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Abstract 
Introduction:  Studies on the effect of 
deletion of ATG5 and ATG7 proteins on 
bone cell function and bone strength in 
laboratory mice have revealed an association 
between autophagy and osteoporosis.  The 
effect on bone strength of the Thr300Ala 
variant (rs2241880 polymorphism) of the 
ATG16l1 gene, a Crohn’s disease 
susceptibility gene essential in macro-
















Methods: 101 Crohn’s disease patients 
underwent DEXA bone density scanning. 
Real time PCR, high resolution melt (HRM) 
and restriction fragment length 
polymorphism (RFLP) were made use of as 
to assess for the rs2241880 polymorphism 
of the ATG16L1 gene in these patients. 
Results:  HRM and RFLP demonstrated 
that 39.6% had the wild type rs2241880 
(Thr300Ala) polymorphism while 7.9% 
were homozygous and 52.5% were 
heterozygous for the polymorphism. Mean 
DEXA bone mineral density scores in these 
patients showed lower T scores at the hip (-
1.74) among patients with the homozygous 
polymorphism than among patients with the 
heterozygous polymorphism (mean T score 
hip:  -1.29).  The highest mean T scores 
were found in patients with the wild type 
polymorphism (-1.04).   
Discussion: This study demonstrates 
the first evidence that polymorphisms in the 
ATG16L1 gene may play a role in bone 
metabolism. 
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Introduction: 
The ATG16l1 (autophagy-related 16-
like) gene, essential in macro-autophagy, is 
located on chromosome 2q37.1.1 The 
Thr300Ala variant (rs2241880 
polymorphism) of this gene, located in the 
c-terminal WD40 domain,1 is an important
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Crohn’s disease (CD) susceptibility gene.  
Osteoporosis is common among CD patients 
2,3 being associated with an increased risk of 
fracture. 
The autophagy pathway appears to play 
an important role in bone metabolism and 
bone diseases, by having a direct effect on 
osteoclast, osteoblast and osteocyte 
function.4 Autophagy maintains cellular 
homeostasis and allows longer-surviving 
cells like osteocytes, to function normally. 
In conditions of increased stress, autophagy 
is increased, resulting in recycling of 
intracellular components like amino acids 
and prolonging cell survival.5 Autophagy 
also allows osteocytes to adjust to a more 
hypoxic and nutrient poor environment. 
Osteocytes play a key role in bone 
remodelling by synthesizing sclerostin, 
receptor activator of nuclear factor kappa B-
ligand (RANKL), fibroblast growth factor-
23 and collagens. Osteocyte autophagy 
plays an important role in age-related bone 
loss.6 Deletion of the autophagy protein 
Atg7 from osteocytes resulted in reduced 
bone mass in mice and suppressed 
autophagy in osteocytes appears to lead to 
age-related bone loss. 
Autophagy is also important in 
osteoclasts, as has been demonstrated using 
conditional knockout mice. Deletion of key 
proteins involved in autophagosome 
formation, like Atg5, resulted in increased 
bone volume in vivo and protection from 
ovariectomy-induced bone loss. Deletion of 
ATG7 was associated with reduced 
resorptive capacity of osteoclasts. This data 
seems to suggest that inhibition of 
autophagy in osteoclasts may provide a 
potential therapeutic mechanism for various 
bone disorders. Osteoclast formation and 
size is increased by hypoxia 7-8 and 
upregulation of autophagy has been shown 
to increase this effect.9 However, 
Rapamycin, an autophagy inducer, has been 
shown to decrease the number of osteoclasts 
and to be associated with reduced bone 
resorption in laboratory rats.10 More in vivo 
and in vitro studies are needed to better 
understand the role of autophagy in 
regulating osteoclast function. 
Osteoblasts are also under autophagic 
control.11 Animal models have shown that 
impaired autophagy is associated with 
severe osteopoenia due to reduced bone 
formation.12 Rapamycin appears to promote 
osteoblast differentiation therefore 
suggesting that autophagy increases bone 
formation while impaired autophagy may be 
associated with an increased risk of 
osteoporosis.13  
Studies analysing the association 
between autophagy and osteoporosis have 
mainly investigated the effect of deletion of 
ATG5 and ATG7 proteins on bone cell 
function and bone strength in laboratory 
mice. No studies on the effect of impaired 
autophagy secondary to polymorphisms in 
the ATG16L1 gene on bone strength in 
humans have been carried out to date.   
Impaired autophagy and CD have both 
been shown to be associated with an 
increased risk for osteoporosis and 
osteopenia. Impaired autophagy has also 
been shown to be one of the pathways 
involved in mucosal inflammation in CD, 
with a higher overall risk of CD in patients 
with the rs2241880 ATG16L1 
polymorphism. However, this 
polymorphism has never been studied as a 
potential risk factor for osteoporosis. We 
therefore hypothesized that CD patients with 
impaired autophagy secondary to the 
rs2241880 ATG16L1 polymorphism have 
lower bone mineral density dual energy X-
Ray absorptiometry (DEXA) scores than 
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Ethical approval was obtained through 
the University of Malta Research and Ethics 
Committee. Maltese CD patients diagnosed 
through standard clinical, histo-pathological 
and endoscopic findings were recruited 
prospectively through the gastroenterology 
clinic at Mater dei Hospital (MDH), Malta.14  
All CD patients seen at medical out-patients 
between September 2012 and June 2014 
were invited to participate.  Patients with 
indeterminate colitis and individuals who 
did not have Maltese ancestry were not 
included in the research.  CD diagnosis was 
defined according to the Copenhagen 
Diagnostic Criteria.15 Written informed 
consent was obtained from each patient.  
Each patient was asked questions related to 
his duration, type, location and severity of 
Crohn’s disease, ongoing and previous 
treatments and the duration of this treatment, 
history of previous fractures and the 
aetiology behind such fractures.  Where 
possible, this information was corroborated 
with information from the patients’ files. All 
data was entered into a tailor-made database.  
All patients underwent a DEXA bone 
mineral density scan at the MDH using a 
Hologic DEXA scanner.  T score 
(comparison of bone density with peak bone 
mass at around age 30) was used to assess 
risk of fracture with T scores <-2.5 being 
indicative of osteoporosis and T scores 
between -1 and -2.5 being suggestive of 
osteopenia. However, since a section of the 
population included young, premenopausal 
women and men younger than 50 years of 
age, the Z score was also used as a marker 
of bone density.16 
Genotyping for the common coding 
variant rs2241880 (Thr300Ala) of the 
ATG16l1 gene was carried out on peripheral 
venous blood extracted from the CD 
patients.  Three millilitres of whole blood 
was extracted from each patient and 
collected in an ethylenediamine tetraacetic 
acid (EDTA) tube. Deoxyribonucleic acid 
(DNA) extraction from whole blood of these 
CD patients was carried out using the DNA 
Mini Kit (Qiagen, Hilden, Germany).17  
Gradient polymerase chain reaction (PCR) 
was then carried out to establish the optimal 
annealing temperature for this variant.  Real-
time PCR and high resolution melt (HRM) 
were subsequently carried out at annealing 
temperatures of 54ºC (optimal temperature 
found at gradient PCR).  The reaction 
mixture for real time-PCR and HRM 
consisted of 4.0µl of 5x Hot FirePol® 
EvaGreen® qPCR Mix Plus (Solis 
BioDyneTM), 0.5µl of 10µM primers F and 
R, 14.0µl of distilled water and 1µl of 
template DNA. The samples were then run 
through qRT-PCR and HRM under the 
following conditions: initiation at 95ºC for 5 
minutes, denaturation at 95ºC for 10 
seconds, annealing at 54ºC for 30 seconds, 
extension at 72ºC for 10 seconds 
(denaturation, annealing and extension were 
repeated for 40 cycles) and HRM at 75–95 
ºC.  The results obtained using HRM were 
then compared with the results of restriction 
enzyme digest of the PCR product.  
Restriction fragment length polymorphism 
(RFLP) was carried out using the 
SfaNI/LweI enzyme (NEB Inc).  The 
reagent mixture consisted of 2µL of NE 
Buffer 4 (X10), 1µL of the SfaNI/LweI 
enzyme (2,000 units/mL), 9µL of DNase 
and RNase free water, and 8µL of the DNA 
under study (0.5-1µg/µL). 5µl of this 
mixture was added to 2µl of 6X DNA 
loading dye buffer double blue and then 
loaded on 2.5% agarose gel.  5µl of 100 
base pair DNA Ladder were also loaded on 
the same gel. The electrophoresis was run 
for 1 hour and 30 minutes at 100 Volts and 






Original Article  
 
    Malta Medical Journal     Volume 29 Issue 03 2017                                                                                                                              
                                               
 
 
mutant and wild type samples. 
Kruskall-Wallis test and χ2 test were 
used to analyse for any statistical differences 
in the phenotypic characteristics of patients 
with the wild type, heterozygous and 
homozygous rs2241880 polymorphisms.  
Kruskall-Wallis test was also used to assess 
whether there were any statistically 
significant differences in bone mineral 
density T scores and Z scores in patients 
with the wild type, heterozygous and 
homozygous rs2241880 polymorphisms.  
 
Results 
Demographic and Phenotypic 
Characteristics 
One hundred and one (101) patients 
with CD were recruited. This represents 
approximately 25% of the Maltese CD 
population and should therefore be a truly 
representative sample of the Maltese CD 
cohort.  Table 1 demonstrates the 
phenotypic characteristics of these patients.  
The mean duration of CD was 8.2 years 
(range: 5 months to 32 years). Table 2 
describes the relevant drug history of the CD 
patients in the study population.  
 
Table 1: Phenotypic characteristics of CD cohort 
Characteristics  
Current Age, mean, (years) [range] 39.9 [18-83] 
Male 51 patients 
Postmenopausal Women 13 % 
Patients with family history of IBD 4 % 
Current Smokers 20 % 
ex- smokers 6 % 
Documented fractures 7 patients 
Hip 1 patient 
Spine 1patient 
Others 5 patients 










Perianal disease 5% 
Extra-intestinal manifestations : 21% 
H/o IBD related abdominal surgery 25% 
A1 - age at diagnosis <17 years; A2 – age at diagnosis 17-40 years; A3 – age at diagnosis >40 
years; L1 – ileal disease only; L2 – colonic disease only; L3 – ileocolonic disease; B1 – non-
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Table 2: Medical Treatment 
Treatment Number of patients (mean dose) 
 5-Amino- Salicylates 82 % 
Thiopurines 55 % 
Current steroid use 7 % 
Previously or currently on steroids 69% 
Previously on anti-TNF -alpha 7% 
Currently on anti-TNF-alpha 37% 
5 mg/kg every 8 weeks 31% 
10 mg/kg every 8 weeks 5% 
5 mg/kg every 4 weeks 1% 
Dual Immunosuppressant Use  
(anti-TNF-alpha and Thiopurine) 
28% 
Previous  Elemental Diet  3% 
Methotrexate 6% 
Calcium and Vitamin D replacement 11% 
Bisphosphonates 2% 
TNF : Tumour necrosis factor; mg – milligrams; kg – kilograms 
 
Table 3: Mean T and Z scores at the Hip and Spine 
 Mean T Score  
(Normal: -1.0 to 1.0) 
Mean Z score 
Hip -1.22 
(Range:-5.2 to 1.2) 
0.55 
(Range:-3.6 to 1.68) 
Spine -0.80 
(Range:-5.1 to 1.6) 
-0.41 
(Range:-2.2 to 1.9) 
 
Bone Densitometry Results 
Table 3 describes the mean T and Z 
scores at the hip and spine. Eleven percent 
(11%) of patients had osteoporosis at the hip 
(T score <-1.5) and 6% had osteoporosis at 
the spine while 46% had osteopenia at the 
hip (T score -1.0 to -2.5) and 34% had 
osteopenia at the spine.  Seven patients had 
documented fractures. Two patients had rib 
fractures and humeral fractures.  These were 
all related to major trauma (motor vehicle 
accidents). Another 3 individuals had 
Colles’ fractures and rib fractures related to 
minor trauma (fall from low height).  
The mean T score (hip) among these 5 
patients was -1.0 (Z score: -0.5) and mean T 
score (spine) was -1.2 (Z score: -1.0). One 
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with no documented trauma (DEXA bone 
mineral density T score spine: -2.86, Z score 
spine: -2.07) and one patient had a hip 
fracture following a fall from her own height 
(T score hip: -2.3, Z score hip: -1.7). 
Two patients with a previous history of 
fractures (one had a hip fracture and the 
other patient had a vertebral fracture) were 
being administered oral bisphosphonates. 
Both patients had a T score less than -2.5 
(mean T score: -3.6). All patients on 
Vitamin D and calcium replacement 
treatment (11%) had a T score less than -1.0 
(mean T score -1.9). 
 
Genotype Analysis 
HRM (sample on Figure 1a) on the 101 
DNA samples from the study population 
revealed that 39.6% of the CD patients (40 
patients) did not have the rs2241880 
(Thr300Ala) polymorphism (wild type) 
while 7.9% (8 patients) were homozygous. 
The rest, 52.5% (53 patients) were 
heterozygous for the polymorphism. These 
results were confirmed by RFLP (Figure 
1b).   
Phenotypic differences between 
patients with wild type, homozygous and 
heterozygous rs2241880 polymorphisms 
were then analysed (Table 4).  Using the 
chi-squared (χ2) test, there were no 
significant differences in the age at 
diagnosis (p: 0.21) of CD, disease location 
(p: 0.73), disease behaviour (p: 0.36), 
history of surgical intervention (p: 0.46) and 
smoking history (p: 0.26) between patients 
with the wild type, heterozygous and 
homozygous rs2241880 polymorphism. 
There were also no significant differences in 
the use of thiopurine therapy (χ2 test p: 
0.12), corticosteroids (p: 0.83), anti-TNFα 
therapy (p: 0.78) and use of dual 
immunosuppression therapy (thiopurine and 
anti-TNF alpha) (p: 0.82) between patients 
with the wild type, heterozygous and 
homozygous rs2241880 polymorphism. 
There was no significant differences in 
disease duration (Kruskall –Wallis test p: 
0.22) and body mass indices (p: 0.52) 
between patients with the wild type, 
heterozygous and homozygous rs2241880 
polymorphism. 
The mean T and Z scores at the hip and 
spine of patients with the wild type and 
mutant genotypes are shown in Table 1.  
There was no statistically significant 
difference in the T score at the hip between 
patients with the wild type, heterozygous 
and homozygous ATG16L1 rs2241880 
variants (Kruskall-Wallis test p: 0.09). 
Similarly, there were no significant 
differences in the mean T score spine (p: 
0.48), Z score hip (p: 0.23) and Z score 
spine (p: 0.73) between patients with the 
wild type and mutant ATG16L1 variants. 
However, a trend in DEXA T scores was 
observed with patients with the homozygous 
rs2241880 polymorphism (T300A variant) 
having lower T scores than patients with the 
heterozygous and wild type polymorphisms.  
Subgroup analysis on 13 postmenopausal 
CD women in our population revealed that 3 
patients exhibited the wild type 
polymorphism, 2 had the homozygous and 8 
had the heterozygous polymorphism.  Mean 
T scores (hip) among postmenopausal 
women demonstrated a similar trend to that 
seen in the CD population (mean T score 
wild type: -0.1, heterozygotes: -1.19, 
homozygotes: -2.58).  A similar trend was 
also seen at the spine (mean T score wild 
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Figure 1: a). High Resolution Melt using 5x Hot FirePol® EvaGreen® qPCR Mix Plus for Exon 
9 (Thr300Ala) of the ATG16L1 gene with rs2241880 primers using DNA from Crohn’s disease 
patient samples b). Agarose gel analysing Restriction Fragment Length Polymorphism for the 
Thr300Ala variant (rs2241880 polymorphism) using the SfaNI/LweI enzyme on DNA 
extracted from Crohn’s disease study patient samples (bp: base pairs, B: blank sample, NA: 
code for Crohn’s disease samples, WT: Wild Type allele, Hetero: Heterozygous allele, Homo: 






















An association between autophagy and 
bone metabolism has recently been 
established.5-13, 18   However, the effect of 
impaired autophagy secondary to ATG16L1 
polymorphisms on bone strength has never 
been studied. In this study, we have 
analysed whether individuals with impaired 
autophagy secondary to the rs2241880 
ATG16L1 polymorphism have lower bone 
mineral densities than individuals not 
exhibiting this polymorphism. This analysis 
was carried out on a population of CD 
patients since this polymorphism has been 
shown to be an important CD susceptibility 
gene in several population studies.19-20 In 
addition, CD is associated with lower bone 
mineral densities and higher risk of 
osteoporosis. While many phenotypic 
characteristics have been identified as 
possible risk factors for osteoporosis in CD 
(age at onset, history of surgical 
intervention, male gender, corticosteroid 
use), studies linking CD susceptibility genes 
with risk for osteoporosis have not been 
carried out.  Further evidence to the validity 
of our cohort is that the clinical 
characteristics of our cohort was very 
similar to that reported in other European 
countries.21-22 
Genotyping of the CD study population 
was carried out using both RFLP and HRM. 
The results from both techniques were 
identical, allowing us to confirm the 
ATG16L1 variant genotypes of our 
population with two different techniques.  
Statistical analysis did not show any 
significant differences in the phenotypic and 
clinical characteristics of patients with wild 
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ATG16L1 polymorphisms.  Statistical 
analysis also did not reveal any significant 
differences in DEXA bone mineral density 
T scores and Z scores between patients with 
the wild type, heterozygous and 
homozygous polymorphisms. However, a 
trend in the mean DEXA T scores at the hip 
and spine may be observed with lower T 
scores in patients with the heterozygous 
allele and with the lowest scores in patients 
with the homozygous allele (Table 4). A 
significant value might have been obtained 
if a larger cohort was studied. 
 
Table 4: Phenotypic characteristics and mean DEXA bone mineral density scores of patients 
with wild type, heterozygous and homozygous rs2241880 polymorphism 
 Wild Type (n=40) Heterozygous (n=53) Homozygous (n=8) 
Gender (male:female) 22:18 26:27 3:5 
Smoking 28%) 28%) 0 
Mean body mass index 
(kg/m2) 
25.6 25.9 24.5 
Montreal Classification 
A1 17.5% 11% 0 
A2 67.5% 64% 50% 
A3 15%  25% 50% 
L1 27.5% 21% 25% 
L2 32.5% 32% 50% 
L3 40% 47% 25% 
B1 67.5% 36 (68% 87.5% 
B2 22.5%) 15 (28%) 0 
B3 4 (10%) 2 (4%) 1 (12.5%) 
Perianal Disease 1 (2.5%) 4 (7.5%) - 
Medical and Surgical Management 
Thiopurine) 50% 66%  7.5% 
anti-TNF-alpha 42.5% 36% 25% 
Dual 
immunosuppression 
(thiopurine + anti-TNF 
alpha) 
27.5% 28% 25% 
Surgical Intervention 27.5% 17% 25% 
Mean DEXA Score 
T Score Hip -1.04  -1.29 -1.74  
T Score Spine -0.72 -0.86  -0.88  
Z Score Hip -0.35  -0.68  -0.58  
Z score Spine -0.40  -0.46  -0.02  
Age of onset(A) A1: <17 years, A2: 17-40 years, A3: >40 years; Disease location (L) L1: ileal 
disease, L2: colonic disease, L3: ileocolonic disease, Behaviour (B) : B1: non-stricturing, non-
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Studies on osteoclasts, osteocytes and 
osteoblasts have shown that impaired 
autophagy results in impaired bone mass 
while the autophagy inducer Rapamycin 
increases bone formation.5-13 These studies 
suggest that impaired autophagy, including 
impaired autophagy secondary to genetic 
variations, results in impaired bone 
formation.  Our findings demonstrate that 
gene polymorphisms in the autophagy 
ATG16L1 gene may be linked to lower bone 
mineral density scores.  Larger prospective 
studies are however required before this link 
may be put into clinical practice.   While 
this study was not powered enough to show 
a statistically significant association 
between bone density results and impaired 
autophagy, the trend in decreasing T scores 
in patients with the rs2241880 
polymorphism should encourage functional 
studies on osteocyte, osteoblast and 
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